Search
Skip to Search Results- 4Trastuzumab
- 2Breast cancer
- 1 Genome wide association study
- 1 SNP(s)
- 1 Single Nucleotide Polymorphism
- 1Breast cancer
-
Anti-Cancer Mechanism of Trastuzumab via Blocking Nuclear HER2 Function and Epigenetic Mechanism of Resistance
DownloadSpring 2020
HER2 receptor tyrosine kinase (encoded by ERBB2 gene) is overexpressed in approximately 25% of all breast cancer tumors (known as HER2-positive breast cancers). Overexpression of HER2 causes overactivation of downstream receptor tyrosine kinase pathways including PI3K/Akt and MAPK pathways and is...
-
Fall 2013
Breast cancer is the most common malignancy among females, and the second leading cause of cancer death among Canadian women. Despite improved survival, both short and long term detrimental effects have been observed with both novel and conventional anti-cancer therapies. In particular, the...
-
Identification and Characterization of a Novel Premenopausal Breast Cancer Locus and Insights into Copy Number Variations for Disease Predisposition and Prognosis
DownloadFall 2018
Breast cancer is a complex multifactorial disease with the interplay of genetic, environmental and lifestyle factors contributing to the disease risk. Studies based on twins estimated that ~30% of the risk is due to genetic factors. High and moderate penetrant mutations along with low penetrance...
-
Understanding the effects of therapeutic HER2 antibodies trastuzumab and pertuzumab on HER2-mediated cell signaling
DownloadFall 2020
The ErbB family of receptor tyrosine kinases, also called the HER receptors, consists of four members including epithelial growth factor receptor (EGFR), erbB2 (HER2), erbB3 (HER3), and erbB4 (HER4). HER2 overexpression has been reported in 20-30% of breast cancer cells and is responsible for...
-
Understanding the Mode of Action of Trastuzumab to Design a Better Therapy for ErbB2-positive Human Breast Cancer
DownloadSpring 2016
Overexpression of ErbB2 occurs in about 25-30% of breast cancer cases and therefore, represents an attractive therapeutic target for treating breast cancer. There are two models for ErbB2 inhibitors that are currently in clinical use: humanized antibodies directed against ErbB2 and small molecule...